Clinical protocols for the treatment of gastrointestinal cancer

胃肠道癌是美国肿瘤相关死亡的主要原因之一。目前的治疗选择仅限于手术、化疗、放疗和分子靶向治疗，迫切需要新的治疗选择。NCI-20-C-0022：VB-111与纳武单抗联合治疗转移性结直肠癌（mCRC）患者的II期试验。NCI-19-C-0033：Nivolumab的II期研究（抗PD 1）、他达拉非和口服万古霉素治疗难治性原发性肝细胞癌或结直肠癌或胰腺癌肝显性转移癌患者; NCI-17-C-0092：Pexa-Vec溶瘤病毒联合免疫检查点抑制治疗难治性结直肠癌的I/II期研究; NCI-17-C-0082：一项在晚期胆道癌（BTC）受试者中进行的Pembrolizumab（一种抗PD-1单克隆抗体）联合卡培他滨和奥沙利铂（CAPOX）治疗的II期研究; NCI-16-C-0135：在肝细胞癌（HCC）或胆道癌（BTC）受试者中联合免疫检查点抑制与消融治疗的初步研究; NCI-15-C-0027：免疫检查点抑制（Durvalumab联合或不联合曲美木单抗）联合放射治疗不可切除胰腺癌患者的初步研究。

Gastrointestinal cancer represents one of the major reasons for tumor related death in the United States. Current treatment options are limited to surgery, chemotherapy, radiation therapy and molecular targeted therapy and new treatment options are urgently needed. We have been enrolling patients on the following protocols:NCI-20-C-0022: Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC). NCI-19-C-0033:Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers; NCI-17-C-0092: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer; NCI-17-C-0082: A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC); NCI-16-C-0135: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) ; NCI-15-C-0027: A Pilot Study of Immune Checkpoint inhibition (Durvalumab with or without Tremelimumab) in Combination with Radiation Therapy in Patients with Unresectable Pancreatic Cancer.